Pfizer Inc. (NYSE:PFE) Shares Sold by Cambridge Trust Co.

Cambridge Trust Co. decreased its position in Pfizer Inc. (NYSE:PFE) by 7.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 67,564 shares of the biopharmaceutical company’s stock after selling 5,824 shares during the quarter. Cambridge Trust Co.’s holdings in Pfizer were worth $1,875,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Ironvine Capital Partners LLC lifted its holdings in shares of Pfizer by 2.1% during the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after purchasing an additional 353 shares during the last quarter. Advisor OS LLC lifted its stake in Pfizer by 1.0% in the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after acquiring an additional 365 shares in the last quarter. Safeguard Investment Advisory Group LLC lifted its stake in Pfizer by 3.9% in the 4th quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock worth $288,000 after acquiring an additional 371 shares in the last quarter. Lantz Financial LLC lifted its stake in Pfizer by 1.3% in the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 381 shares in the last quarter. Finally, Wellington Shields Capital Management LLC lifted its stake in Pfizer by 1.3% in the 1st quarter. Wellington Shields Capital Management LLC now owns 30,750 shares of the biopharmaceutical company’s stock worth $853,000 after acquiring an additional 385 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday. Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $34.58.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.22 during midday trading on Friday, hitting $30.43. 42,364,712 shares of the company were exchanged, compared to its average volume of 37,871,120. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The firm has a market cap of $172.43 billion, a P/E ratio of -507.08, a PEG ratio of 1.07 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.19. The firm has a 50 day simple moving average of $28.73 and a 200-day simple moving average of $27.84.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.31% and a negative net margin of 4.66%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Research analysts forecast that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.52%. Pfizer’s dividend payout ratio is -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.